Indaptus Therapeutics Stock Short Ratio
| INDP Stock | USD 7.30 0.86 10.54% |
Indaptus Therapeutics' fundamental analysis aims to assess its intrinsic value by examining key economic and financial indicators - such as cash flow records, changes in balance sheet accounts, income statement trends, financial ratios, and relevant microeconomic factors affecting Indaptus Stock price.
Indaptus | Short Ratio | Build AI portfolio with Indaptus Stock |
Indaptus Therapeutics Company Short Ratio Analysis
Indaptus Therapeutics' Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.
Current Indaptus Therapeutics Short Ratio | 0.02 X |
Most of Indaptus Therapeutics' fundamental indicators, such as Short Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Indaptus Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Indaptus Short Ratio Driver Correlations
Understanding the fundamental principles of building solid financial models for Indaptus Therapeutics is extremely important. It helps to project a fair market value of Indaptus Stock properly, considering its historical fundamentals such as Short Ratio. Since Indaptus Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Indaptus Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Indaptus Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
The higher the Short Ratio, the longer it would take to buy back the borrowed shares. In theory, the more short positions are currently outstanding, the faster it will be to cover shorted positions.
| Competition |
Based on the latest financial disclosure, Indaptus Therapeutics has a Short Ratio of 0.02 times. This is 99.49% lower than that of the Biotechnology sector and 99.73% lower than that of the Health Care industry. The short ratio for all United States stocks is 99.5% higher than that of the company.
Indaptus Short Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Indaptus Therapeutics' direct or indirect competition against its Short Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Indaptus Therapeutics could also be used in its relative valuation, which is a method of valuing Indaptus Therapeutics by comparing valuation metrics of similar companies.Indaptus Therapeutics is currently under evaluation in short ratio category among its peers.
Indaptus Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Indaptus Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Indaptus Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Indaptus Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Indaptus Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Indaptus Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Indaptus Therapeutics' value.| Shares | Morgan Stanley - Brokerage Accounts | 2025-03-31 | 884 | Bank Of America Corp | 2025-03-31 | 98.0 | Ubs Group Ag | 2025-03-31 | 87.0 | Wells Fargo & Co | 2025-03-31 | 64.0 | Jpmorgan Chase & Co | 2025-03-31 | 17.0 | Group One Trading, Lp | 2025-03-31 | 7.0 | Susquehanna International Group, Llp | 2025-03-31 | 0.0 | Bangor Savings Bank | 2025-06-30 | 0.0 | Citadel Advisors Llc | 2024-12-31 | 0.0 | Vanguard Group Inc | 2025-03-31 | 256.3 K | Investment House Llc | 2025-03-31 | 128.9 K |
Indaptus Fundamentals
| Return On Equity | -2.59 | ||||
| Return On Asset | -1.22 | ||||
| Current Valuation | 348.89 K | ||||
| Shares Outstanding | 572.66 K | ||||
| Shares Owned By Insiders | 19.42 % | ||||
| Shares Owned By Institutions | 6.00 % | ||||
| Number Of Shares Shorted | 14.72 K | ||||
| Price To Book | 1.49 X | ||||
| EBITDA | (15.02 M) | ||||
| Net Income | (15.02 M) | ||||
| Cash And Equivalents | 33.01 M | ||||
| Cash Per Share | 4.00 X | ||||
| Total Debt | 84.16 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 9.18 X | ||||
| Book Value Per Share | 4.89 X | ||||
| Cash Flow From Operations | (12.32 M) | ||||
| Short Ratio | 0.02 X | ||||
| Earnings Per Share | (41.44) X | ||||
| Target Price | 56.0 | ||||
| Beta | 1.17 | ||||
| Market Capitalization | 4.18 M | ||||
| Total Asset | 7.34 M | ||||
| Retained Earnings | (60.44 M) | ||||
| Working Capital | 3.22 M | ||||
| Net Asset | 7.34 M |
About Indaptus Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Indaptus Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Indaptus Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Indaptus Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Additional Tools for Indaptus Stock Analysis
When running Indaptus Therapeutics' price analysis, check to measure Indaptus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Indaptus Therapeutics is operating at the current time. Most of Indaptus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Indaptus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Indaptus Therapeutics' price. Additionally, you may evaluate how the addition of Indaptus Therapeutics to your portfolios can decrease your overall portfolio volatility.